地棘蛙素-B用于晚期上皮性卵巢癌的II期试验。一项西南肿瘤学组的研究。
Phase II trial of didemnin-B in advanced epithelial ovarian cancer. A Southwest Oncology Group study.
作者信息
Cain J M, Liu P Y, Alberts D E, Gallion H H, Laufman L, O'Sullivan J, Weiss G, Bickers J N
机构信息
Puget Sound Oncology Consortium, Seattle, WA.
出版信息
Invest New Drugs. 1992 Apr;10(1):23-4. doi: 10.1007/BF01275473.
A Phase II study of Didemnin-B, a marine cyclic depsipeptide, was undertaken in patients with progressive epithelial ovarian cancer. The starting dose was 2.6 mg/m2. Fifteen patients received the drug, of whom twelve were evaluable. There were no responses observed in the twelve patients. The two most frequent toxicities were nausea and vomiting and anemia. On the basis of this trial, Didemnin-B is not felt to have significant effect with epithelial ovarian cancer.
对海洋环缩肽Didemnin-B进行了一项II期研究，研究对象为进展期上皮性卵巢癌患者。起始剂量为2.6mg/m²。15名患者接受了该药物治疗，其中12名可进行评估。这12名患者中未观察到缓解情况。两种最常见的毒性反应是恶心、呕吐和贫血。基于该试验，Didemnin-B对上皮性卵巢癌未显示出显著疗效。
Zotero 插件